Novavax Inc (NVAX)

Novavax Inc (NVAX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.9B; returns 1 day -2.9%, 1 week -13.9%, 1 year +16.0%.

Novavax, Inc. is a biotechnology company focused on developing and commercializing vaccines for infectious diseases using its recombinant nanoparticle technology and Matrix-M adjuvant. While initially focused on a COVID-19 vaccine, Nuvaxovid, the company has transitioned lead commercial responsibility for it to Sanofi for the 2025-2026 season.

Groups NVAX belongs to

• Shrinking Share Count
• Biotechnology
• Healthcare
• Pharmaceuticals
• Infectious Diseases
• Biopharmaceutical
• COVID-19
• Life Sciences
• Commercial Stage
• Royalty Streams
• Strategic Partnerships

NVAX financial model: income statement, cash flow and balance sheet